Slide #1

Slide #2



Slide #3

Slide #4



Slide #5



Slide #6



Slide #7

Current DES Are Out Of Favor

- "Anti-Platelet Hassle Factor"
  - Balance long-term anti-platelet therapy with future medical and dental requirements
- Increased stent thrombosis and revascularization rates
  - Delayed or incomplete healing
- Poor deliverability
  - Suboptimal profile and flexibility

Annual sales of drug-eluting stents have dropped by ~$1.0 billion from $5.4 billion in 2006

MIV THERAPEUTICS INC.

7

Slide #8

MIV DES Combine A Novel NanoPorous HAp Surface Modification With Lipid Drug Delivery Technologies And Release Drug In Capsules

The hydroxyapatite lattice provides the structural rigidity required to allow the use of lipid drug delivery technologies that deliver drug in capsules

The drug mixtures are loaded into the hydroxyapatite pores forming an ultra flexible drug delivery coating that is 0.6 microns thin and extremely durable



MIV DES do not require more time or resources to manufacture than current DES and have current DES-like margins

MIV THERAPEUTICS INC.

8

Slide #9



Slide #10

Slide #11



Slide #12



Slide #13



Slide #14



Slide #15



Slide #16



Slide #17



Slide #18



Slide #19



Slide #20



Slide #21



Slide #22



Slide #23



Slide #24



Slide #25



Slide #26



Slide #27

The VESTASYNC-I FIM Study Met Its Primary Safety And Efficacy Endpoints. Matched QCA Analysis Of 12 pts At 4 And 9 Months Showed No Increase In LLL (P=0.9)

Variable (n=15)	In-Stent 4-Month	In-Segment 4-Month
MLD, mm	2.34 ± 0.36	2.02 ± 0.37
% Diameter stenosis	13.8 ± 7.0	23.6 ± 8.8
Late lumen loss, mm	**0.30 ± 0.25**	**0.16 ± 0.29**
Restenosis*, % (n)	0.0 (0)	0.0 (0)

Variable (n=12**)	In-Stent 4-Month	In-Segment 4-Month	In-Stent 9-Month	In-Segment 9-Month
MLD, mm	2.33 ±0.34	2.05±0.37	2.27 ± 0.33	2.02 ± 0.29
% Diameter stenosis	±	±	15.9 ± 8.2	23.6 ± 9.5
Late lumen loss, mm	**0.31 ± 0.26**	**0.17 ± 0.32**	**0.37 ± 0.24**	**0.20 ± 0.31**
Restenosis*, % (n)	0.0 (0)	0.0 (0)	0.0 (0)	0.0 (0)

** Defined as diameter stenosis ≥ 50% at angiographic follow up*
*** 3 patients refused 9-month follow up*
Abizaid et al ACC 2008

MIV THERAPEUTICS INC

27

Slide #28

LLL By QCA At 4 And 9 Months



MIV THERAPEUTICS INC

28

Slide #29

Matched IVUS Analysis Of 11 Patients At 4 And 9 Months Showed No Increase In NIH Volume Or Percentage Obstruction (P=0.8)

Variable	Baseline n=14*	4-Month n=14*
Vessel Volume (mm^3)	276.7 ± 117.1	276.6 ± 84.8
Stent Volume (mm^3)	145.7 ± 14	142 ± 0.5
Lumen Volume (mm^3)	145.8 ± 47.5	138.8 ± 33.5
NIH Volume (mm^3)	N/A	**3.9 ± 3.3**
Malapposition Volume (mm^3)	0.15 ± 0.5	0.09 ± 0.3
% Stent Obstruction	N/A	**2.6 ± 2.22**

Variable	4-Month N= 11 P*	9-Month N= 11 P*
Vessel Volume (mm3)	286.9 ± 87.4	296.8 ± 85.6
Stent Volume (mm3)	140.5 ± 36.7	143.1 ± 41.4
Lumen Volume (mm3)	136.3 ± 34.2	136.8 ± 38.2
NIH Volume (mm3)**	**4.3 ± 3.5**	**6.1 ± 4.9**
Malapposition Volume (mm3)	0.14 ± 0.34	0.13 ± 0.36
% Stent Obstruction**	**2.8 ± 2.2**	**3.8 ± 2.3**

** IVUS consul malfunction has prevented retrieval of data for patient #14*
*** 3 patients refused 9-month follow up*
Abizaid et al ACC 2008

MIV THERAPEUTICS INC

29

Slide #30

IVUS % Obstruction 4 And 9 Months



MIV THERAPEUTICS INC

30

Slide #31

No Major Cardiac Events
No Plavix For 8 Months

Variable	Patients (n=15)
In-hospital	
Death, n(%)	0
MI, n(%)	0
TLR, n(%)	0
Stent thrombosis, n(%)	0
4-month follow-up	
Death, n(%)	0
MI, n(%)	0
TLR, n(%)	0
TVR, n (%)	0
Stent thrombosis, n(%)	0
9-month follow-up	
Death, n(%)	0
MI, n(%)	0
TLR, n(%)	0
TVR, n (%)	0
Stent thrombosis, n(%)	0

MIV THERAPEUTICS INC

31

Slide #32

Robust Clinical Trial Pipeline

	VESTASYNC II	VESTASYNC III / VESTA-FIM	VESTASYNC IV
Product	VESTAsync™	VESTAsync™/ VESTAcor™	VESTAsync™
Start Date	May 2008	June /June 2008	July 2008
Clinical Investigator	Abizaid	TBD/Serruys	TBD
Location	Brazil	India /Rotterdam	India
Number of Patients	120	30 /15	100
Follow-Up	9 Months	9 Months	9 Months

MIV THERAPEUTICS INC

32

Slide #33

Slide #34

Slide #35


Innovation Drives Valuation
• Differentiated approach and a strong patent position
• Strong proof of concept in animals and humans
• Opportunity to revolutionize DES therapy and significantly expand the stent market and usage
MIV
THERAPEUTICS INC.
35